RECRUITINGOBSERVATIONAL

Reward Processing and Depressive Subtypes: Identifying Neural Biotypes

Reward Processing and Depressive Subtypes: Identifying Neural Biotypes Related to Suicide Risk, Resilience, and Treatment Response

About This Trial

Deficits in motivation and pleasure are common in depression, and thought to be caused by alterations in the ways in which the brain anticipates, evaluates, and adaptively uses reward-related information. However, reward processing is a complex, multi-circuit phenomenon, and the precise neural mechanisms that contribute to the absence or reduction of pleasure and motivation are not well understood. Variation in the clinical presentation of depression has long been a rule rather than an exception, including individual variation in symptoms, severity, and treatment response. This heterogeneity complicates understanding of depression and thwarts progress toward disease classification and treatment planning. Discovery of depression-specific biomarkers that account for neurobiological variation that presumably underlies distinct clinical manifestations is critical to this larger effort.

Who May Be Eligible (Plain English)

* Our studies require some in-person visits to our research lab, located at 42nd Ave and Clement St in San Francisco. - Because this study includes an MRI, part of the screening process will be to ensure you don't have any metal in your body, you do not have head or neck tattoos, and you are comfortable inside the MRI scanner. Who May Qualify: - 18-70 years with a diagnosis of major depressive disorder (MDD) for MDD group, or without for unaffected comparison (UC) group - Negative metal screen for MRI safety - Normal (or corrected to normal) vision Who Should NOT Join This Trial: - Past or present neurological problems (including seizures and head trauma resulting in neurological or cognitive symptoms) - Loss of consciousness (LOC) greater than 30 minutes or any LOC with neurologic symptoms - Major medical conditions (e.g., seizure disorders, treatment with anticonvulsant medication, endocrine disorders, significant cardiac pathology) - Substance dependence, within the past year, or failed urine toxicology on the day of neuroimaging sessions - Known claustrophobia - Current Pregnancy - IQ estimate \< 70 Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

* Our studies require some in-person visits to our research lab, located at 42nd Ave and Clement St in San Francisco. * Because this study includes an MRI, part of the screening process will be to ensure you don't have any metal in your body, you do not have head or neck tattoos, and you are comfortable inside the MRI scanner. Inclusion Criteria: * 18-70 years with a diagnosis of major depressive disorder (MDD) for MDD group, or without for unaffected comparison (UC) group * Negative metal screen for MRI safety * Normal (or corrected to normal) vision Exclusion Criteria: * Past or present neurological problems (including seizures and head trauma resulting in neurological or cognitive symptoms) * Loss of consciousness (LOC) greater than 30 minutes or any LOC with neurologic symptoms * Major medical conditions (e.g., seizure disorders, treatment with anticonvulsant medication, endocrine disorders, significant cardiac pathology) * Substance dependence, within the past year, or failed urine toxicology on the day of neuroimaging sessions * Known claustrophobia * Current Pregnancy * IQ estimate \< 70

Treatments Being Tested

OTHER

cross-sectional MRI and EEG assessments (NO INTERVENTION)

n/a there is no intervention in this observational study

Locations (1)

San Francisco Healthcare System

San Francisco, California, United States